Eledon Pharmaceuticals (ELDN) Cash & Equivalents (2013 - 2026)
Eledon Pharmaceuticals (ELDN) posted Cash & Equivalents of $6.2 million for Q1 2026, down 73.03% on a QoQ basis from $22.8 million in Q4 2025, and down 95.07% year-over-year from $124.9 million in Q1 2025.
Eledon Pharmaceuticals (ELDN) Cash & Equivalents (2013 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $6.2 million for Q1 2026.
- Quarterly Cash & Equivalents fell 95.07% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (down 95.07% YoY) and the FY2025 annual result came in at $22.8 million, up 10.99% from the prior year.
- Cash & Equivalents was $6.2 million for Q1 2026 at Eledon Pharmaceuticals, down from $22.8 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $124.9 million in Q1 2025 and bottomed at $3.7 million in Q3 2023.
- A 5-year average of $27.0 million and a median of $9.2 million in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2025 — Cash & Equivalents soared 2108.66% — and 2026, when it sank 95.07%.
- Eledon Pharmaceuticals' Cash & Equivalents stood at $56.4 million in 2022, then slumped by 91.82% to $4.6 million in 2023, then jumped by 345.56% to $20.5 million in 2024, then increased by 10.99% to $22.8 million in 2025, then tumbled by 73.03% to $6.2 million in 2026.
- Business Quant data shows ELDN's Cash & Equivalents at $6.2 million in Q1 2026, $22.8 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 2.83 Mn |
| 4 | BeOne Medicines | 469.68 Bn | 464.89 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.76 Bn | 115.51 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 70.40 Bn | 61.65 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Eledon Pharmaceuticals | 401.92 Mn | 401.92 Mn | - | 6.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.15 Mn |
| Dec 31, 2025 | 22.81 Mn |
| Sep 30, 2025 | 3.67 Mn |
| Jun 30, 2025 | 5.74 Mn |
| Mar 31, 2025 | 124.90 Mn |
| Dec 31, 2024 | 20.55 Mn |
| Sep 30, 2024 | 6.75 Mn |
| Jun 30, 2024 | 26.04 Mn |
| Mar 31, 2024 | 5.66 Mn |
| Dec 31, 2023 | 4.61 Mn |
| Sep 30, 2023 | 3.67 Mn |
| Jun 30, 2023 | 40.95 Mn |
| Mar 31, 2023 | 46.50 Mn |
| Dec 31, 2022 | 56.41 Mn |
| Sep 30, 2022 | 65.89 Mn |
| Jun 30, 2022 | 9.20 Mn |
| Mar 31, 2022 | 9.20 Mn |
| Dec 31, 2021 | 9.30 Mn |
| Sep 30, 2021 | 94.04 Mn |
| Jun 30, 2021 | 101.13 Mn |